Roche: Barclays raises its target price

(CercleFinance.com) - Barclays has raised its target price for Roche from 275 to 290 Swiss francs, including the royalty on orforglipron, for which initial Phase III data (in type 2 diabetes) are expected mid-year.


Although fourth-quarter results for 2024 were mixed, the core EPS target for 2025 exceeded our forecasts, leading us to raise our figures", adds the broker the day after the Swiss healthcare group's annual results.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.